Frailty Assessments in Personalized Treatment for Older Adults with Multiple Myeloma: A Case Study
Authors of this article discuss the role of frailty assessments in managing older adults with multiple myeloma (MM). Frailty scores, including the IMWG score, are valuable tools for...
CNP, DipACLM Nurse Practitioner, Massachusetts General Hospital
Dupilumab Effectively Manages Lenalidomide-Induced Rash in Patients With Multiple Myeloma
Lenalidomide (Len) is a crucial treatment for multiple myeloma (MM), improving progression-free survival (PFS), but it often causes a rash that leads to dose reductions or interruptions. Len rash occurs...
Daratumumab: Durable Efficacy in Heavily Treated Multiple Myeloma
Daratumumab monotherapy demonstrated promising efficacy and a manageable safety profile in heavily pretreated patients with multiple myeloma in a pooled, post-hoc analysis of the GEN501 and SIRIUS studies. The combined...
Study Reveals Need for Better Therapies in Triple-Class Exposed Multiple Myeloma
The LocoMMotion study, a multinational prospective observational trial, examined the effectiveness and safety of real-world clinical practice treatments in triple-class exposed patients with multiple myeloma who had received proteasome inhibitors,...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Elevating Myeloma Care: Daratumumab Plus Lenalidomide/Bortezomib/Dexamethasone Sets a New Standard
Advances in myeloma treatment have significantly improved patient outcomes, with the combination of lenalidomide, bortezomib, and dexamethasone (RVd) becoming a cornerstone of care....
